MIT Professor’s Moderna Stake on Brink of Topping $1 Billion

About This Source - Bloomberg QuickTake

QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.

Bloomberg L.P. is a privately held financial, software, data, and media company headquartered in Midtown Manhattan, New York City. It was founded by Michael Bloomberg in 1981, with the help of Thomas Secunda, Duncan MacMillan, Charles Zegar, and a 12% ownership investment by Merrill Lynch.

Recent from Bloomberg QuickTake:

  • New York Governor Cuomo: Trump Administration Fueling “Politics of Division”
  • U.S. Protests: Mayor de Blasio Responds to Police Vehicle Driving Into Crowd in New York
  • NASA Administrator Explains Weather Mishap Ahead of Second Try for Historic SpaceX Launch
  • Another early investor of Moderna Inc. is on the cusp of owning a stake worth at least $1 billion after the biotech firm reported encouraging early trial results for an experimental Covid-19 vaccine.

    The value of board member Bob Langer’s 3.2% holding, including stock options, rose to $934.3 million Monday, as the shares surged 20% to a record $80 each. Langer, a professor at the Massachusetts Institute of Technology, would be at least the third individual with Moderna holdings topping $1 billion, joining Chief Executive Officer Stephane Bancel and Harvard University professor Timothy Springer.

    Moderna, whose shares have more than quadrupled this year, released interim data from a small phase 1 trial showing positive early signs that the vaccine can create an immune system response to the virus in humans. The news helped fuel a broader surge in stocks, with the S&P 500 Index advancing 3.2%, the most since April 8.

    The company priced a stock offering to fund manufacturing of its coronavirus vaccine at $76 a share, 5% below the last close, people familiar with the deal said after Monday’s market trading.

    Langer, 71, has licensed or sub-licensed patents to more than 400 biotech, pharmaceutical, chemical and medical companies, according to his biography at MIT’s Langer Lab.

    Bancel and Springer own stakes worth $2.45 billion and $1.38 billion, respectively, according to the Bloomberg Billionaires Index. The biggest beneficiary of the stock surge is top shareholder Flagship Pioneering Inc., a firm started by Moderna co-founder Noubar Afeyan. Flagship distributed 10 million shares to investors last week, leaving it with an 11% stake worth $3.27 billion. Afeyan declined to elaborate when asked about how much of the stock he owns individually.

    “The broader market reaction is a measure of the need people have to perceive that there’s a scientific, technological solution to this kind of battle,” Afeyan said in a phone interview. “We’ve increased expectations, but that hasn’t changed what we do.”

    Bancel and other Moderna executives, including outgoing Chief Financial Officer Lorence Kim and President Stephen Hoge, have been selling shares, some through prearranged trading plans. Bancel has sold about 200,000 shares since Feb. 21, data compiled by Bloomberg show.

    Moncef Slaoui, who owned 82,508 shares as of Feb. 21, stepped down from Moderna’s board last week and plans to divest his stake to help lead “Operation Warp Speed,” a Trump administration effort involving the private and public sectors to accelerate the development of a vaccine, the company said in an emailed statement.

    Slaoui intends to donate the incremental value accrued from his Moderna stake since the May 14 close to cancer research, Caitlin Oakley, a spokeswoman for the U.S. Department of Health & Human Services, wrote in an email.

    Other major shareholders include AstraZeneca Plc and Theleme Partners, the hedge fund of Patrick Degorce, a former partner of the Children’s Investment Fund.

    Like Moderna, other companies that are developing coronavirus vaccines have seen their shares surge. With stock gains of more than 70% in 2020, Shenzhen Kangtai Biological Products Co. Chairman Du Weimin’s net worth now stands at $6.7 billion, while that of Chongqing Zhifei Biological Products Co. Chairman Jiang Rensheng has risen to $8.1 billion. Seo Jung-jin, chairman of Celltrion Inc., is South Korea’s second-richest man, with a net worth of $7.3 billion.

    Subscribe to our YouTube channel: https://bit.ly/2TwO8Gm

    QUICKTAKE ON SOCIAL:
    Follow QuickTake on Twitter: twitter.com/quicktake
    Like QuickTake on Facebook: facebook.com/quicktake
    Follow QuickTake on Instagram: instagram.com/quicktake
    Subscribe to our newsletter: https://bit.ly/2FJ0oQZ
    Email us at quicktakenews@gmail.com

    QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.

    In This Story: COVID-19

    Covid-19 is the official WHO name given to the novel coronavirus which broke out in late 2019 and began to spread in the early months of 2020.

    Symptoms of coronavirus

    The main symptoms of coronavirus are:

    • a persistent new cough (non productive, dry)
    • a high temperature (e.g. head feels warm to the touch)
    • shortness of breath (if this is abnormal for the individual, or increased)

    Latest News about Covid-19

    Below are stories from around the globe related to the 2020 outbreak of novel Coronavirus – since the WHO gave the Covid-19 naming. Most recent items are posted nearest the top.

    5 Recent Items: COVID-19

  • ‘That’s the way science works’: Fauci fires back at critics
  • BREAKING: Euro 2020 – Two England players isolating after contact with Billy Gilmour
  • Brian Moore’s Full Contact Rugby: Bob Skinstad & Matt Proudfoot on Springboks’ chances vs the Lions
  • COVID Delta variant spreading fast, comprises 99% of UK cases | Newsfeed
  • Ranked Choice Voting Makes New York City’s Mayoral Race Tough to Call
  • In This Story: Donald Trump

    Donald John Trump was the 45th President of the United States. Before entering politics, he was a businessman and television personality. Trump was born and raised in Queens, a borough of New York City, and received a bachelor’s degree in economics from the Wharton School.

    5 Recent Items: Donald Trump

  • Senate Democrats who supported the filibuster now oppose it
  • Iran’s merchants find costly workarounds to US economic sanctions
  • Leo Terrell sounds off on Stacey Abrams’ latest voter ID comments
  • Haberman: Trump is preparing for an indictment
  • Mark Meadows: Media sided with China because of ‘animosity’ for Trump
  • In This Story: Moderna

    Moderna is an American biotechnology company based in Cambridge, Massachusetts that focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.

    CEO: Stéphane Bancel (2011–)

    Stock ticker: (NASDAQ:MRNA)

    5 Recent Items: Moderna

  • Canadians who got AstraZeneca COVID-19 vaccine as 1st dose confused
  • Canada to receive 68M doses of COVID-19 vaccine by end of July | FULL
  • COVID-19 vaccine rule for Broadway show raises travel concerns for AstraZeneca recipients
  • mRNA COVID-19 vaccines preferred 2nd doses after AstraZeneca shot, Canada’s NACI says | FULL
  • GP’s to start administering Pfizer vaccine | Coronavirus | 9 News Australia
  • In This Story: S&P

    S&P Global that publishes financial research and analysis on stocks, bonds, and commodities. One division of the business, S&P Global Ratings, is considered the largest of the Big Three credit-rating agencies, which also include Moody’s Investors Service and Fitch Ratings.

    2 Recent Items: S&P

  • Final Trades: H&R Block, S&P Health Care, General Motors & more
  • Lumber prices soar 275% in the pandemic, shutting out homebuilders: CNBC After Hours
  • Leave a Comment